Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hematologic Neoplasms × DT2216 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Azacitidine 11 venetoclax 7 AP 1903 reagent 6 Itraconazole 5 fludarabine 4 fedratinib 4 belinostat 4 Rituximab 4 Cytarabine 4 Bortezomib 4 ARQ531 4 pomalidomide 3 ibrutinib 3 daratumumab 3 cc-486 3 angiotensin I (1-7) 3 Lenalidomide 3 Imatinib Mesylate 3 Dexamethasone 3 Daunorubicin 3 Cyclophosphamide 3 tosedostat 2 tazemetostat 2 tanespimycin 2 talquetamab 2 tafasitamab 2 romidepsin 2 pembrolizumab 2 ixazomib 2 glasdegib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04886622 2025-04-16

A Study of DT2216 in Relapsed/Refractory Malignancies

Dialectic Therapeutics, Inc

Phase 1 Completed

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡